Ocugen Inc. (OCGN)
Ocugen Eyes 3 Retinal Gene Therapy Filings as Late-Stage Pipeline Advances
Ocugen NASDAQ: OCGN outlined plans to advance three late-stage retinal disease programs, with company speaker Shankar saying the company is targeting biologics license applications for retinitis pigmentosa and Stargardt disease next year and a third BLA for geographic atrophy in 2028.
Ocugen (OCGN) Upgraded to Buy: Here's Why
Ocugen (OCGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
OCGN Falls on Wider Q1 Loss Despite Strong Pipeline Progress Outlook
Ocugen swings to a wider Q1 loss as costs climb, but pipeline milestones and gene therapy data keep its long-term plans on track.
Ocugen, Inc. (OCGN) Q1 2026 Earnings Call Transcript
Ocugen, Inc. (OCGN) Q1 2026 Earnings Call Transcript
Ocugen (OCGN) Reports Q1 Loss, Beats Revenue Estimates
Ocugen (OCGN) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to a loss of $0.05 per share a year ago.
OCGN's Gene-Agnostic Strategy Could Reset Retinal Therapy
Ocugen's gene-agnostic therapy strategy targets broad retinal patient groups with one-time treatments, setting up major 2026-27 catalyst events.
Ocugen Stock Outlook: Valuation, Cash Runway and Dilution Risk
Ocugen offers upside from a packed 2026 catalyst calendar, but cash runway limits and dilution risk keep the pre-commercial biotech outlook finely balanced.
OCGN Gene Therapy Pipeline: Key 2026-27 Catalysts Ahead
Ocugen faces a packed 2026-27 catalyst window with filings, interim data and Phase III readouts across three one-time retinal gene therapies.
Ocugen (OCGN) Up 2.9% Since Last Earnings Report: Can It Continue?
Ocugen (OCGN) reported earnings 30 days ago. What's next for the stock?
OCGN Completes Early Enrollment in Pivotal Stargardt Disease Study
Ocugen completes GARDian3 enrollment early as OCU410ST gene therapy targets Stargardt disease with no approved treatments. Data readouts are expected in Q3.
Ocugen Falls as Gene Therapy for Eye Disease Lags in Phase II Study
OCGN stock falls after phase II data for OCU410 show lower lesion reduction than earlier results, despite 31% improvement in the eye disease study.
Ocugen, Inc. (OCGN) Discusses Top Line Results From Phase II ArMaDa Trial of OCU410 in Geographic Atrophy Transcript
Ocugen, Inc. (OCGN) Discusses Top Line Results From Phase II ArMaDa Trial of OCU410 in Geographic Atrophy Transcript
